Literature DB >> 29877043

Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study.

Paola Monari1, Ruggero Moro1, Alberico Motolese2, Cosimo Misciali3, Carlotta Baraldi3, Pier Alessandro Fanti3, Stefano Caccavale4, Mario Puviani5, Daniela Olezzi5, Pierfrancesco Zampieri6, Giusto Trevisan7, Katiuscia Nan7, Chiara Fiorentini8, Giovanni Pellacani9, Giulio Gualdi1.   

Abstract

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterised by painful, necrotic ulcerations. PG is described as a rare disease: the world-wide incidence is estimated to be around 3 to 10 cases per million population per year. These estimations are based mostly on case reports and retrospective case series; there are no prospective, multicentre studies on the matter. The apparent rarity of PG is in contrast with our clinical perception as dermatologists: in our opinion, PG is not so uncommon. Therefore, we decide to investigate the epidemiology of PG in the Italian population and confirm our clinical suspicions that it is not an orphan disease. We enrolled all patients diagnosed with PG in 8 Italian Dermatological Departments from 1st October 2014 to 1st November 2015, and we recorded their features. Our data, collected from 64 patients, are in accordance with those of the published literature regarding the epidemiology and features of PG. In an Italian population of roughly 8 million inhabitants of 7 provinces, we found an incidence of 5.17 new cases per million population per year. Unlike our predictions before the study, we confirmed the world-wide incidence of PG. To our knowledge, this is the first observational, multicentre study on PG. We hope that it provides a stimulus for further researches on PG and for the creation of an Italian register.
© 2018 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiology; pyoderma gangrenosum

Mesh:

Year:  2018        PMID: 29877043      PMCID: PMC7949684          DOI: 10.1111/iwj.12939

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  30 in total

1.  PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome.

Authors:  X Calderón-Castrat; D Bancalari-Díaz; C Román-Curto; A Romo-Melgar; D Amorós-Cerdán; L A Alcaraz-Mas; E Fernández-López; J Cañueto
Journal:  Br J Dermatol       Date:  2016-04-19       Impact factor: 9.302

2.  PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.

Authors:  Rosita Saraceno; Graziella Babino; Andrea Chiricozzi; Arianna Zangrilli; Sergio Chimenti
Journal:  J Am Acad Dermatol       Date:  2015-01       Impact factor: 11.527

3.  Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014.

Authors:  Stanislav N Tolkachjov; Aodhnait S Fahy; David A Wetter; Kevin R Brough; Alina G Bridges; Mark D P Davis; Rokea A El-Azhary; Marian T McEvoy; Michael J Camilleri
Journal:  J Am Acad Dermatol       Date:  2015-07-21       Impact factor: 11.527

Review 4.  Skin ulcers misdiagnosed as pyoderma gangrenosum.

Authors:  Roger H Weenig; Mark D P Davis; Patrick R Dahl; W P Daniel Su
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

Review 5.  Drug-Induced Pyoderma Gangrenosum: A Review.

Authors:  Jane Y Wang; Lars E French; Neil H Shear; Afkham Amiri; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403

6.  Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013.

Authors:  Naiara S Barbosa; Stanislav N Tolkachjov; Rokea A El-Azhary; Mark D P Davis; Michael J Camilleri; Marian T McEvoy; Alina G Bridges; David A Wetter
Journal:  J Am Acad Dermatol       Date:  2016-07-26       Impact factor: 11.527

7.  Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome.

Authors:  Markus Braun-Falco; Oleksandr Kovnerystyy; Peter Lohse; Thomas Ruzicka
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

8.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.

Authors:  Emmanuella Guenova; Anna Teske; Birgit Fehrenbacher; Sebastian Hoerber; Annette Adamczyk; Martin Schaller; Wolfram Hoetzenecker; Tilo Biedermann
Journal:  Arch Dermatol       Date:  2011-06-16

9.  Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study.

Authors:  Paola Monari; Ruggero Moro; Alberico Motolese; Cosimo Misciali; Carlotta Baraldi; Pier Alessandro Fanti; Stefano Caccavale; Mario Puviani; Daniela Olezzi; Pierfrancesco Zampieri; Giusto Trevisan; Katiuscia Nan; Chiara Fiorentini; Giovanni Pellacani; Giulio Gualdi
Journal:  Int Wound J       Date:  2018-06-06       Impact factor: 3.315

10.  Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene.

Authors:  Angelo V Marzano; Valentina Trevisan; Marco Gattorno; Isabella Ceccherini; Clara De Simone; Carlo Crosti
Journal:  JAMA Dermatol       Date:  2013-06       Impact factor: 10.282

View more
  9 in total

Review 1.  A novel topical therapy for resistant and early peristomal pyoderma gangrenosum.

Authors:  Wendy A Pearson; David A Prentice; Deborah L Sinclair; Lee Y Lim; Keryln J Carville
Journal:  Int Wound J       Date:  2019-07-12       Impact factor: 3.315

2.  Ulcerative pyoderma gangrenosum.

Authors:  Megan Sander; Michael Sander
Journal:  CMAJ       Date:  2019-09-23       Impact factor: 8.262

3.  Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study.

Authors:  Paola Monari; Ruggero Moro; Alberico Motolese; Cosimo Misciali; Carlotta Baraldi; Pier Alessandro Fanti; Stefano Caccavale; Mario Puviani; Daniela Olezzi; Pierfrancesco Zampieri; Giusto Trevisan; Katiuscia Nan; Chiara Fiorentini; Giovanni Pellacani; Giulio Gualdi
Journal:  Int Wound J       Date:  2018-06-06       Impact factor: 3.315

4.  Management of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report.

Authors:  Alina Nazir; Ali Zafar
Journal:  Cureus       Date:  2022-05-21

5.  Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.

Authors:  Marcella Ricardis May; Albert Rübben; Andrea Lennertz; Luk Vanstreels; Marike Leijs
Journal:  J Pers Med       Date:  2022-01-27

6.  Pyoderma Gangrenosum in an African American Male Initially Presenting as Sepsis.

Authors:  Carly E Wallace; Amit Sharma
Journal:  Cureus       Date:  2022-01-25

7.  Pyoderma Gangrenosum After Insertion of a Hemodialysis Catheter: Koebner Phenomenon, Systemic Inflammatory Response Syndrome, and a Delay in Diagnosis.

Authors:  Majed M Alosaimi; Fatemah Sebzali; Ali Iqbal; Christian G Rabbat; Catherine M Clase
Journal:  Can J Kidney Health Dis       Date:  2022-09-20

8.  Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.

Authors:  Rotem Semo Oz; Oluwakemi Onajin; Liora Harel; Rotem Tal; Tomas Dallos; Adena Rosenblatt; Lukas Plank; Linda Wagner-Weiner
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-05       Impact factor: 3.054

9.  Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study.

Authors:  Khalaf Kridin; Arieh Solomon; Rimma Laufer Britva; Dana Tzur Bitan; Arnon D Cohen
Journal:  Immunol Res       Date:  2021-04-22       Impact factor: 2.829

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.